We are live on ! Find out more
IMDX

Insight Molecular Diagnostics
IMDX

41 hedge funds and large institutions have $62.1M invested in Insight Molecular Diagnostics in 2026 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 7

83% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 6

17% more funds holding

Funds holding: 35 → 41 (+6)

0.78% more ownership

Funds ownership: 58.09% → 58.87% (+0.78%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

50% less capital invested

Capital invested by funds: $125M → $62.1M (-$62.8M)

Holders
41
Holders Change
+6
Holders Change %
+17.14%
% of All Funds
0.5%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
17
Increased
11
Reduced
6
Closed
7
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
-$4K

Top Buyers

1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$4.88M
2
BC
Broadwood Capital
New York
+$3.03M
3
HCM
Heights Capital Management
California
+$2.28M
4
FIA
FNY Investment Advisers
New York
+$1.2M
5
FOR
Family Office Research
Maryland
+$739K

Top Sellers

1
Jane Street
Jane Street
New York
-$319K
2
6CM
683 Capital Management
New York
-$280K
3
Goldman Sachs
Goldman Sachs
New York
-$180K
4
Citadel Advisors
Citadel Advisors
Florida
-$117K
5
Renaissance Technologies
Renaissance Technologies
New York
-$101K
Name Holding Trade Value Shares
Change 		Change in
Stake
OAC
26
OMERS Administration Corp
Ontario, Canada
$34.4K -$90.9K -15,664 -60%
PAG
27
Private Advisor Group
New Jersey
$34.2K – – –
VGA
28
Vanguard Global Advisers
Pennsylvania
$18.9K +$33.5K +5,775 New
EWA
29
EverSource Wealth Advisors
Alabama
$16.4K – – –
ASN
30
Advisory Services Network
Georgia
$10.2K +$18K +3,100 New
Citigroup
31
Citigroup
New York
$2.67K +$4.73K +814 +81,400%
GSEP
32
Golden State Equity Partners
California
$1.48K +$2.61K +450 New
SS
33
SBI Securities
Japan
$607 – – –
JP Morgan Chase
34
JP Morgan Chase
New York
$393 – – –
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$210 +$197 +34 +113%
PSB
36
Piscataqua Savings Bank
New Hampshire
$81 – – –
CCWM
37
Cassaday & Co Wealth Management
Virginia
$33 +$58 +10 New
AFG
38
Albion Financial Group
Utah
$23 – – –
CIAM
39
Caitong International Asset Management
Hong Kong
$3 +$6 +1 New
FFA
40
Farther Finance Advisors
California
$3 +$6 +1 New
FDCDDQ
41
Federation des caisses Desjardins du Quebec
Quebec, Canada
$3 +$6 +1 New
Jane Street
42
Jane Street
New York
– -$319K -42,469 Closed
Goldman Sachs
43
Goldman Sachs
New York
– -$180K -23,965 Closed
Citadel Advisors
44
Citadel Advisors
Florida
– -$117K -15,647 Closed
Renaissance Technologies
45
Renaissance Technologies
New York
– -$101K -13,400 Closed
Hudson Bay Capital Management
46
Hudson Bay Capital Management
Connecticut
– -$98K -13,061 Closed
Bank of America
47
Bank of America
North Carolina
– -$2.51K -335 Closed
TRCT
48
Tower Research Capital (TRC)
New York
– -$1.88K -250 Closed
1
2

IMDX Hedge Fund Activity: Q1 2026 in Review

41 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2026, worth a combined $62.1M — down 50% from $125M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new IMDX positions and 7 closed out — a net gain of 10 holders — while 11 added to existing stakes and 6 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $4.88M. The largest seller was Jane Street, exiting entirely with an estimated $319K sold.

  • 41 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2026, up from 35 in Q4 2025.
  • Funds reported $62.1M of Insight Molecular Diagnostics stock for Q1 2026, down 50% quarter-over-quarter.
  • 17 funds opened new Insight Molecular Diagnostics positions in Q1 2026 and 7 closed out, a net change of +10 holders.
  • The largest Insight Molecular Diagnostics buyer in Q1 2026 was Alyeska Investment Group, an estimated $4.88M added.
  • The largest Insight Molecular Diagnostics seller in Q1 2026 was Jane Street, an estimated $319K sold.

Based on aggregated 13F filings for Q1 2026.